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Rheumatoid arthritis
AbstrAct
Objective to analyse whether early arthritis patients 
who do not fulfil the american college of rheumatology/
european league against rheumatism (acr/eUlar) 2010 
classification criteria for rheumatoid arthritis (ra) have a 
different course of the disease dependent on whether they 
can or cannot be classified as ra because of radiographic 
disease (eUlar task force) at diagnosis.
Methods For this observational study within the Swiss 
ra cohort ScQM, we included patients with early 
undifferentiated arthritis (disease duration ≤1 year), 
who had not received any previous disease-modifying 
antirheumatic drugs (DMarDs). 2010 acr/eUlar criteria 
negative patients were separated into two groups 
(radiographic vs non-radiographic arthritis) depending on 
whether or not they had radiographic changes defined 
as erosive disease by a eUlar task force (≥3 joints 
with erosions). the primary outcome measure was the 
radiographic progression detected employing the ratingen 
erosion score. Health assessment Questionnaire (HaQ) and 
DaS-28 were used as secondary outcome measures. the 
average observation period was 4 years.
Results a total of 592 patients were analysed. 240 were 
not classifiable as ra by application of the 2010 acr/eUlar 
criteria at baseline. in 57 patients, radiographs at the first visit 
were not available. 133 patients had radiographic arthritis 
and 50 non-radiographic arthritis. treatment was initiated 
in all patients with DMarDs, mostly methotrexate. no 
differences in DaS-28 and HaQ scores were found during 
follow-up. the average erosion scores were higher among 
patients with initially radiographic arthritis throughout the 
study. the progression of erosion scores over time, however, 
was higher in patients with initially non-radiographic 
arthritis with less subsequent radiological progression (3.3 
erosions/year vs 0.4, respectively, p<0.0001).
Conclusions the clinical and radiographic course of 
early undifferentiated arthritis under treatment was not 
dependent on the presence of erosions in three or more 
joints (ie, the definition of radiographic disease by the 
eUlar task force) at diagnosis in our cohort.
InTROduCTIOn
A task force of specialists from both the Euro-
pean League Against Rheumatism (EULAR) 
and the American College of Rheumatology 
(ACR) have proposed the 2010 ACR/EULAR 
classification criteria for rheumatoid arthritis 
(RA).1 These 2010 ACR/EULAR classification 
criteria define RA in patients with a score of 
at least 6 of possible 10. In addition, ‘patients 
with erosions typical of RA’ were deemed to 
have ‘prima facie evidence of RA and can be 
classified as such’.1 However, the definition of 
‘erosions typical for RA’ was not provided in 
the manuscript.
A definition of ≥2 erosions being typical for 
RA had been evaluated in 518 patients with 
Key messages
What is already known about this subject?
 ► according to the european league against 
rheumatism (eUlar) task force, rheumatoid ar-
thritis (ra) can be classified in american college 
of rheumatology (acr)/eUlar 2010 classification 
criteria negative patients as  three or more joints 
that are erosive.
What does this study add?
 ► the clinical and radiographic course in acr/eUlar 
2010 negative patients under treatment was not 
dependent on the presence of erosions in three or 
more joints at diagnosis in our cohort.
How might this impact on clinical practice?
 ► all patients suspected of ra should be treated equal-
ly until the clinical course demonstrates whether 
clinical remission and radiographic non-progression 
can be achieved.
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undifferentiated arthritis of the Leiden cohort in 20092 
showing that 53% of these patients will develop the full 
picture of RA. An analysis of the ESPOIR (Étude et Suivi 
des POlyarthritites Indifférencées Récentes) and Leiden 
cohorts3 employed as definition the start of methotrexate 
(MTX) or any other disease-modifying antirheumatic 
drug (DMARD) within the first year and persistency over 
5 years. This analysis showed a specificity of 85%–95% 
for the definition of at least three joints with erosions 
depending on the outcome used in the patients who did 
not fulfil the 2010 ACR/EULAR criteria (ACR/EULAR 
negative). Based on these data, a EULAR task force has 
now defined erosive disease4 for the use in the 2010 
ACR/EULAR rheumatoid arthritis classification criteria, 
as at least three erosions (defined as a cortical break) 
at three different sites of the proximal interphalangeal 
joints, MCP, MTP or the wrist (counted as one joint). The 
major issue with such an analysis is how to define an early 
arthritic disease to be severe enough to fulfil the require-
ments being a chronic inflammatory disease as RA.
The definition of this consensus statement has, so far, 
not been applied in another study population. The aim of 
the study presented here was to evaluate if ACR/EULAR 
negative early arthritis patients have a different course 
of the disease dependent on whether they can be classi-
fied as RA because of radiographic disease at diagnosis 
or not, with regard to development of new joint erosions 
(primary end point), disease activity (DAS-28 and Health 
Assessment Questionnaire (HAQ)) and the therapeutic 
strategy.
MeTHOds
study population and design
The Swiss Clinical Quality Management in rheuma-
toid arthritis (SCQM) is a population-based and hospi-
tal-based RA cohort, which has been described in 
detail elsewhere.5 6 In brief, the SCQM is a population 
of patients with RA and patients with undifferentiated 
arthritis (UA). The diagnosis, independent on whether 
it was RA or UA, was established by the treating rheuma-
tologist.
In this study, we restricted our analysis to patients 
with early arthritis. The analysis included data collected 
between January 1998 and November 2011. Inclusion 
criteria for the analysis were a diagnosis of early arthritis 
by a rheumatologist, defined as less than 1 year of dura-
tion after the first symptoms and at least one follow-up 
visit. Patients treated with glucocorticoids, synthetic or 
biological DMARDs for more than 31 days before the 
first visit were excluded from the analysis. Other exclu-
sion criteria were missing 28 joint counts or radiographs 
at baseline.
Retrospective assessment of the ACR/euLAR 2010 
classification criteria
Patients with RA and UA were retrospectively classified 
employing the 2010 ACR/EULAR criteria at the time of 
the first data entry. Joint counts were assessed according 
to the 2010 ACR/EULAR criteria resulting in different 
scores for either tender and/or swollen joints: a score of 
0 meant no joint involvement, a score of 2: 1–3 joints, a 
score of 3: 4–10 joints and a score of 5: >10 joints. Posi-
tive acute-phase reactants were equivalent to a score of 
1. C reactive protein (CRP)/erythrocyte sedimentation 
rate (ESR) was positive if greater than 9 mg/L or 27 
mm/h, respectively. Disease duration scored for 1 if ≥6 
weeks. For anti-citrullinated peptides antibodies (ACPA) 
and rheumatoid factor, a score of 0 was attributed to 
double-negative patients and a score of 2 to single-pos-
itive patients. If a patient was double positive, a score 
of 3 was assigned. This adaptation has been validated 
before in the same patient population.7 The cumula-
tive score for joint count, acute phase reactants, disease 
duration and rheumatoid factor/ACPA was calculated 
for every patient. Patients were defined as 2010 ACR/
EULAR positive if the cumulative score was higher than 
5 and as ACR/EULAR negative if below 6.1 For this anal-
ysis, we selected for 2010 ACR/EULAR negative patients. 
In these patients, the Ratingen score was evaluated for 
the presence or absence of ≥3 joints at disease onset. In 
the Ratingen score, up to 5 points can be obtained per 
joint or erosion. Therefore, radiographs from patients 
at disease onset were re-evaluated by two experienced 
rheumatologists (RBM and JvK, both with >15 years of 
experience) to set the definition of radiographic disease 
as erosions in ≥3 joints at disease onset. This analysis 
was restricted to radiographs of hands and feet. In the 
event of disagreement between the readers with regard 
to the classification as radiographic or non-radiographic 
disease, a consensus was found.
Outcome parameters
The primary endpoint was the radiographic progres-
sion during follow-up. The radiographic outcome was 
analysed on serial radiographs according to the number 
and the size of bone erosions. Erosions were measured 
prospectively using a validated scoring system (Ratingen 
score), based on the amount of joint-surface destruction 
for each joint. The Ratingen score is a validated scoring 
method to analyse radiographs of patients with arthritis.8 
It scores 28 joints for erosions, from 0 to 5 (maximum 
score 190) depending on the destructed surface area 
of the individual joint. The joints analysed are the same 
as in the publication of van der Heijde et al.4 There is 
no evaluation of joint space narrowing. The interob-
server agreement and test–etest reliability are high, as 
published.8
Secondary endpoints were clinical disease progression 
and functional disability. Change of DAS-28 scores were 
analysed in the different patient groups. The DAS-28 
scores were calculated employing the swollen and 
tender joint count, ESR and/or CRP as available. If both 
ESR-DAS and CRP-DAS were available, the average of 
both scores was used as described before.9 10 Functional 
disability was assessed with the HAQ.
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statistical analysis
The baseline disease characteristics of patients in the two 
groups were compared using standard descriptive statis-
tics. Continuous variables were compared using Student’s 
t-test and categorical variables with χ2 test. Curves 
showing changes in DAS-28 and HAQ scores over time 
were created using loess smoothing of the raw data. The 
effect of a positive erosion score (cut-off ≥3 joints) was 
analysed in ACR/EULAR negative patients for DAS-28 
and HAQ scores using linear mixed models with random 
slope and random intercept, and adjusted for various 
baseline factors (time since diagnosis, gender, age, medi-
cation, positivity for rheumatoid factor, DAS-28 at base-
line, Ratingen score at baseline, GAQ-DI at baseline, ESR 
at baseline, ACPA positivity at baseline) in a univariate 
fashion. Slopes of the Ratingen score after diagnosis 
were compared between groups using analysis of vari-
ance (ANOVA). All statistical analyses were two-sided at 
the 0.05 significance level. The analyses were performed 
using Excel (V.14.2.2), the GraphPad Prism 5 software 
and the lme4 package in R (V.3.0.1; R Core Team (2013). 
R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. 
URL http://www. R- project. org/).
ResuLTs
Patients
Of the 9627 patients in the database, 1345 had a disease 
duration of less than 1 year at baseline and 947 patients 
were not pretreated with any glucocorticoids or DMARD 
for more than 31 days at baseline, of which 756 patients 
were diagnosed as RA or UA, of which 609 patients had 
at least one follow-up in the database and of which 592 
patients in the database had valid 28-joint counts at base-
line. The new 2010 ACR/EULAR criteria were applied 
to these patients. In total, 240 patients were not classifi-
able as RA according to the 2010 ACR/EULAR criteria 
(<6 out of 10, 40.5%). We selected 183 of the 240 ACR/
EULAR negative patients with available radiographs at 
the first visit. Fifty of these patients had <3 (referred to 
as non-radiographic UA, ‘nr-UA’) and 133 patients with 
≥3 joints with erosions (referred to as radiographic UA, 
‘rad-UA’) at the baseline visit. The inter-reader reliability 
was 92.3% (data not shown).
Baseline demographical data
The analysis of the demographical data revealed no 
significant differences for age, gender and symptom 
duration at disease onset. The analysis of parameters 
indicative of disease activity demonstrated no significant 
differences for swollen and tender joint count, CRP, ESR 
and DAS-28 scores in patients with nr-UA versus patients 
with rad-UA. Only rheumatoid factor was significantly 
more frequent in patients with nr-UA (χ2 test: 4.408; 
p=0.036), whereas positivity for ACPA did not differ 
significantly between the two groups (table 1).
Initial treatment
One hundred twenty-five patients were initially treated 
with MTX (74%, 66% of rad-UA and nrUA, respectively), 
23 with sulfasalazine (16%, 11% of rad-UA and nrUA, 
respectively), 15 with leflunomide (8% for both rad-UA 
and nrUA) and 15 with hydroxychloroquine (10%, 8% 
of rad-UA and nrUA, respectively). Glucocorticoids 
were employed as an initial treatment in 123 patients 
(figure 1B, 64%, 68% of rad-UA and nrUA, respectively). 
There were no major differences in the initial treatment 
with DMARDs and glucocorticoids between the two 
patient groups (figure 1C).
Change of treatment
The analysis of treatment changes was limited to a 
maximum of five. The data demonstrated that the number 
of patients whose treatment needed adaption decreased 
continuously in both patients groups (figure 1A). In 
detail, the number of newly prescribed glucocorticoids 
and DMARDs decreased with every visit for both patient 
groups (figure 1B and C). The number of patients 
with a newly initiated tumour necrosis factor antago-
nist treatment reached a maximum at the second treat-
ment change and decreased thereafter (figure 1D). No 
differences in the therapeutic strategy between patients 
with rad-UA and nrUA were detected.
Radiographic data
The radiographic progression was analysed employing 
an erosion score (Ratingen). It was assessed sepa-
rately for patients with rad-UA and nr-UA. At disease 
onset (p<0.0001) and continuously during follow-up, 
the mean erosion scores were significantly higher 
in patients with rad-UA as compared with patients 
with nrUA (figure 2A). In contrast, the average yearly 
progression of erosion scores was 3.3 for nrUA and 0.4 
for rad-UA (ANOVA, p<0.0001, figure 2B).
Follow-up of disease activity
The development of disease activity was analysed sepa-
rately for patients with rad-UA and nrUA employing the 
development of DAS-28 scores over time. At disease onset 
and during follow-up, no differences in DAS-28 levels 
could be detected comparing the two patient groups 
(figure 3A).
Patient-related outcome parameter
Personal outcome analysed by HAQ scores revealed no 
differences in patients with rad-UA and nrUA at disease 
onset. After 2 years, the average HAQ scores did not differ 
between patients with rad-UA and nrUA. After 3 years, the 
average HAQ sores increased for patients with rad-UA as 
compared with patients with nrUA (0.17 vs 0.64 nrUA vs 
rad-UA, Student’s t-test: p=0.10, figure 3B).
dIsCussIOn
The new ACR/EULAR criteria were used at the time 
of diagnosis for the classification of 592 patients 
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with early arthritis of the Swiss national cohort SCQM. 
Moreover, 41.4% of these patients were not classifiable 
according to the new ACR/EULAR criteria at disease 
onset. The definition of RA depending on the presence 
of joint erosions defined by a EULAR task force4 was 
applied in patients of the SCQM cohort who did not fulfil 
the 2010 ACR/EULAR criteria. Seventy-three per cent of 
the ACR/EULAR negative patients displayed ≥3 joints 
with erosions at disease onset.
No differences in clinical activity (DAS-28) and 
patient-related outcomes (HAQ) were observed between 
these two groups. In addition, changes in the thera-
peutic regimen were comparable. In general, we think 
that the therapeutic regimen in these patients reflects 
the common practice in Switzerland since patients are 
recruited into the SCQM cohort from academic hospi-
tals as well as from private practices in Switzerland. It is, 
however, not known whether the patients fulfilled the 
2010 ACR/EULAR criteria during follow-up because 
retesting of ACPA and RF was generally not recorded in 
the database, most probably because it was not performed.
The presence of ACPA in both patient groups of our 
cohort may seem rare. Our selection for patients nega-
tive for the 2010 ACR/EULAR criteria may, however, 
be a likely explanation because positivity for rheuma-
toid factor and/or ACPA increases the score by 2–3. 
Selecting for patients with less than a score of 6 needed 
for classification of RA leads, subsequently, to a lower 
frequency of patients achieving a higher score in the four 
subcategories including ACPA.
Despite the similarities in clinical outcome, patients 
with rad-UA showed on average continuously higher 
erosion scores, but a lower slope of radiographic progres-
sion as compared with patients with nrUA during the 
observation period.
Initial radiographic disease is understood as a posi-
tive predictor for evolving other joint erosions.11–13 In 
our cohort, however, the rate of progression in initially 
nrUA was higher than in patients with rad-UA. In both 
groups, erosion scores reached a plateau within the 
second year after disease onset. In ACR/EULAR posi-
tive patients with RA, erosion scores did, in contrast, 
continuously increase despite treatment (data not 
shown). Thus, treatment that did not differ between 
the two groups as shown in figure 1 may eliminate the 
differences in radiographic progression after 1 year in 
patients with UA independently of the radiographic 
status at disease onset. Progression within the first year 
may be predetermined in the phase prior to diagnosis 
when therapy is not yet initiated. Early, aggressive treat-
ment might influence this radiographic progression. 
Furthermore, it has to be taken into consideration 
that as opposed to other cohort data,14 15 non-erosive 
disease at baseline did not correlate with less erosions 
Table 1  Demographical data at baseline
Joints with erosions <3, nrUA ≥3, rad-UA P values
N 50 133 –
Sex (f/m) 37/13 90/43 0.41
Age (years) 46.2±14.1 56.3±13.5 <0.001
Follow-up (months, mean±SD) 58.4±41.9 49.3±34.5 0.16
Symptom duration (days, mean±SD) 173±87 180±101 0.65
SJC at onset (mean±SD) 3.7±2.9 4.0±3.0 0.44
TJC at onset (mean±SD) 4.3±3.0 3.7±3.2 0.23
DAS-28 at onset (mean±SD) 3.7±1.0 3.6±1.3 0.59
RF positive at onset (n, %, mean±SD) 66.6% 50.0% 0.06
RF (titre, mean±SD) 107.8±72.8 115.3±120.8 0.89
ACPA positive at onset (% mean±SD)* 14.3% 25.0% 0.33
ACPA (U/mL, mean±SD) 429.6±253.3 135.4±127.5 0.26
ESR at onset, mm/h (mean±SD) 15.9±13.3 20.2±19.1 0.55
CRP at onset, mg/L (mean±SD) 8±1.1 12.5±4.3 0.02
Ratingen score at onset 0.5±0.7 10.4±7.3 <0.001
Initial treatment (MTX, SSZ, Lef, HCQ, %) 74.0%, 16.0%, 8%, 10% 69.1%, 11.3%, 8.2%, 7.5% –
Initial MTX dose (mean±SD) 12.7±9.2 13.7±4.9 0.25
Concomitant glucocorticoid treatment (%) 64.0% 64.7% 0.92
Glucocorticoid dose (mg/day) 12.5±9.2 11.7±8.4 0.64
*Analysed on patients with available data.
ACPA, anti-citrullinated peptides antibodies; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; f, female; HCQ, 
hydroxychloroquine; Lef, leflunomide; m, male; MTX, methotrexate;  RF, rheumatoid factor; SJC, swollen joint count; SSZ, sulfasalazine; TJC, 
tender joint count.
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during follow-up. A significant difference between 
the SCQM and the ESPOIR and Leiden cohorts may 
be that patients are included into the SCQM database 
not by classification criteria but by clinical diagnosis of 
the rheumatologist based on his experience. Clinical 
judgement and experience rather than application of 
classification criteria may explain why the development 
of erosions within the first year of therapy in patients 
Figure 1  Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent 
therapeutic changes. Treatment changes are depicted numerically from 1 to 5. Med. 1 is equal to the first treatment initiated at 
disease onset. Med. 2 represents an alternative medication used at a subsequent visit, if Med. 1 was changed to another drug, 
independent of the reason for change. The total number of patients is shown who underwent a treatment change independent 
on the particular change (A), change of corticosteroid regimen (B), synthetic DMARD therapy (C), TNF antagonist treatment 
(D) and non-anti-TNF biological treatment (E). Therapeutic decisions for parts B–E of the figure are depicted as percentages 
of decisions taken in the different groups. All patients groups undergoing treatment changes are shown separately for non-
radiographic (black) and radiographic (white) patients. ACR, American College of Rheumatology; DMARD, disease-modifying 
antirheumatic drug; EULAR, European League Against Rheumatism; TNF, tumour necrosis factor.
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with nrUA was anticipated by the treating rheumatol-
ogist. Furthermore, this may explain why such a high 
rate of patients with an erosive disease was detected 
among patients with UA.
In our study, 73% of the ACR/EULAR negative patients 
displayed ≥3 joints with erosions as compared with 11.7% in 
the Leiden cohort, 17.4% in the ESPOIR cohort3 and 5.4% 
published from a Norwegian Very Early Arthritis Clinic.16 In 
Figure 2  Radiological progression. The disease progression was analysed employing the Ratingen erosion score. (A) Average 
Ratingen scores per group are shown. The Ratingen scores were calculated separately for patients with radiographic (solid 
grey) and non-radiographic (solid black) disease. The average yearly progression over the whole follow-up period is depicted 
per patient group as absolute values (B) and a cumulative probability blot (C). For the cumulative probability blot, radiographic 
patients are shown as a solid grey line and non-radiographic patients as a solid black line.
Figure 3  Disease activity. The disease activity, depicted by DAS-28 (left panel) and Health Assessment Questionnaire (HAQ) 
score (right panel), was analysed for every patient. The data are shown as averages for radiographic (dashed line) and non-
radiographic patients (solid line) for every group over 48 months.
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the SCQM cohort, patients with early arthritis were included 
at the discretion of the treating rheumatologist. All were 
then treated with DMARDs. In the ESPOIR cohort, patients 
were diagnosed by a rheumatologist as RA-like or RA17 while 
in the Leiden early arthritis cohort and the Norwegian Very 
Early Arthritis Clinic, all patients with ≥1 joint, symptom 
duration <2 years18 were included. In contrast to the publi-
cations of Knevel et al3 and Thabet et al,2 our study focused 
on the evolving disease. Clinical parameters and erosions 
over the subsequent 5 years and not on the percentage of 
patients fulfilling the ACR/EULAR criteria over time2 or 
requiring DMARD treatment3 were analysed.
However, the importance of erosive disease at disease 
onset4 as a predictor for disease progression cannot be 
confirmed in our cohort of patients with undifferentiated 
arthritis.
To exclude confounding factors for radiographic 
progression, multivariate analyses were performed. No 
influence of either time to diagnosis, gender, age or 
initial DAS, HAQ, ESR or CRP was detected.
The low rate of ACPA in both patient groups may 
seem low. We think that this low rate is not surprising 
as we selected for patients negative for the 2010 ACR/
EULAR criteria. In these criteria, positivity for rheuma-
toid factor and/or ACPA contributes to 2–3 out of 10 
possible points. Selecting for patients not achieving 6 or 
more points needed for classification of RA leads, subse-
quently, to a lower frequency of patients achieving higher 
points in the four subcategories including ACPA.
In conclusion, these data strongly suggest that in the 
SCQM cohort, presence of three or more joints with 
erosions at disease onset does not reliably select patients 
with more clinical activity or radiographic progression 
during the further course of the disease.
In consequence, all patients suspected of RA should 
be treated equally until the clinical course demonstrates 
whether clinical remission and radiographic non-pro-
gression can be achieved.
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